KRAS and non-small cell lung carcinoma: The fibroblast growth factor 1 (FGFR-1) inhibitor ponatinib is currently being tested in combination with trametinib in KRAS mutant NSCLC patients since it is known that this combination induces cell death in KRAS mutant positive tumors in vivo [67] (Clinicaltrials.gov Identifier: NCT03704688 (accessed on 24 February 2021)).